echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Small molecule targeted lung cancer drugs rise! Who will divide the domestic $4.4 billion market

    Small molecule targeted lung cancer drugs rise! Who will divide the domestic $4.4 billion market

    • Last Update: 2019-06-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent years, the incidence rate and mortality rate of lung cancer have been steadily rising, ranking the highest in all cancers worldwide China is no exception The annual growth rate of lung cancer is 26.9%, which is the most important malignant tumor in China The market scale of lung cancer drugs is also growing rapidly From 2010 to 2015, China has nearly tripled to US $3.3 billion The compound annual growth rate reached 21.13% The market is expected to grow further this year, with the introduction of new anti-cancer drugs and the inclusion of some lung cancer drugs in the national medical insurance, the total size is expected to exceed 4.43 billion US dollars The incidence rate of lung cancer is the highest in China and worldwide The annual growth rate of lung cancer is 26.9% in China According to statistics, in 2015, there were 733000 new cases of lung cancer in China, and the early screening method for lung cancer was low-dose spiral CT Although compared with chest radiography, the lung cancer-related mortality of high-risk population after low-dose spiral CT screening was reduced by 20%, but due to the early diagnosis of lung cancer, the 5-year survival rate was only about 20%, and there was still a large clinical demand in the whole field of lung cancer that was not met The histopathological classification of lung cancer is complex, and the subtypes except small cell carcinoma are called NSCLC because of their common characteristics and treatment methods In 2015, about 587000 (80%) of 733000 lung cancer patients were non-small cell carcinoma With the development of targeted treatment, the molecular classification of lung cancer is more and more important The common genotypes of lung cancer include EGFR mutation and a LK rearrangement and ros1 fusion accounted for about 210000 EGFR mutation patients (Figure 1 Classification of lung cancer) the rise of small molecule targeted lung cancer drugs in recent ten years, the drug development of advanced non-small cell lung cancer mainly focuses on small molecule targeted drugs and immunotherapy Currently, NSCLC biomarkers recommended by the national comprehensive cancer network of the United States are: EGFR mutation, ALK rearrangement, ros1 rearrangement, BRAF mutation, etc Other markers such as HER2 and met amplification are still in clinical research (Figure 2 proportion of NSCLC related gene markers and corresponding drugs) at present, tyrosine kinase inhibitor (TKI) has experienced three generations of development The first generation includes gefitinis, erlotini, etc They reversibly bind to EGFR and compete with ATP to inhibit EGFR activation However, with the emergence of the second and third generation, the first generation TKI is gradually replaced The second generation TKI is an improvement on the first generation It is characterized by irreversible binding with epidermal growth factor receptor, reducing the risk of drug miss, so as to delay the progress of the disease But it's a double-edged sword It can also cause serious side effects such as diarrhea, rash and other intolerance The third generation TKI, represented by oxitinib, has corrected these shortcomings and significantly reduced the side effects, which is the solution for T790M drug-resistant mutation EGFR-TKI competitive pattern EGFR-TKI is the most effective drug for the treatment of EGFR mutation positive NSCLC patients Up to now, EGFR-TKI has been developed to the third generation Among them, the three generations of EGFR-TKI oxitinib, which came into the market in 2015, has become a new standard for the first-line treatment of EGFR mutant NSCLC with its excellent clinical efficacy Gefitinib is the first TKI, which can selectively inhibit the activity of EGFR tyrosine kinase It can inhibit the proliferation, metastasis and neovascularization of tumor cells, so as to inhibit the symptoms of metastatic non-small cell lung cancer and improve the survival rate In February 2005, AstraZeneca introduced it to the Chinese market, especially for Asian patients with no smoking history In 2017, the total amount of gefitinib used in public hospitals reached 420 million yuan, accounting for about 28.05% of the market of lung cancer targeted small molecule drugs After being included in the national medical insurance, its growth is expected to further improve The exetinib developed by Beida pharmaceutical industry belongs to the national class 1 new drug It is a small molecule targeted anticancer drug with independent intellectual property rights Exetinib has a number of patents in the world At present, it has been approved to treat advanced non-small cell lung cancer Its chemical structure, molecular mechanism and action are similar to those of gefitinib and erlotinib, but its safety is better In 2016, the total sales of exetane in China's public hospitals was about 1.035 billion yuan, accounting for 24.10% of the small molecule targeted drug market for lung cancer But with a series of targeted drugs added to the national health insurance catalog, exetinib will face new challenges in the future At present, five alk-tki have been listed in the global market, but each alk-tki in China is listed later Clozatinib was first listed in China in 2013, and it is the first small molecule targeting drug approved for ALK positive NSCLC It was not included in the medical insurance until October 2018 Because of its remarkable curative effect, aletinib's sales increased sharply after being listed in 2015, with sales of 450 million US dollars in fiscal year 2018 Seretinib, developed by Novartis, was approved by FDA in May 2017 for first-line ALK positive non-small lung cancer patients However, compared with aleutinib, seretinib has relatively weak efficacy and more side effects, and it is in the second-line position It is worth mentioning that the ensartinib (x-396) of Beida Pharmaceutical Co., Ltd issued a notice on January 23, 2019, saying that the domestic alk-tki ensatenib (x-396) was reviewed by the State Drug Administration after the registration application was accepted Domestic R & D layout has gradually expired in the first generation of EGFR-TKI patents, and many domestic pharmaceutical companies have deployed related generic drugs, such as Qilu pharmaceutical, Kelun pharmaceutical, etc., Qilu pharmaceutical is the first generic drug to be listed in China in terms of gefitinib, which was approved to be listed in December 2016 and passed the consistency evaluation in December 2017; erlotini zhongchuano and xinlitai have successively compared with 2017 And 2018 In the team of alk-tki generic drugs, hausen and Cohen are at the forefront, and have submitted listing applications successively With the approval of generic drugs and the implementation of the volume purchase policy, the cost of the next generation of EGFR-TKI will be significantly reduced, which will lead to the increase of the utilization rate, and even is expected to turn advanced NSCLC into chronic disease treatment Main reference materials: [1] detailed explanation of EGFR target: large indication market, the first domestic third generation TKI declared for listing [2] prediction and analysis of market scale and development trend of China's lung cancer drug industry in 2018
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.